Stamford man cycles 150 miles with colleagues in support of workmate

Wendy Butler with the cyclists, including Simon Eacott, fourth from left
Wendy Butler with the cyclists, including Simon Eacott, fourth from left
Have your say

A MAN cycled 150 miles from Banbury Cross to Charing Cross to help raise a fantastic sum of money for charity.

Simon Eacott, 46, of Little Casterton Road, Stamford, took part in a three-day cycle ride in support of his work colleague and friend Wendy Butler who is terminally ill with pancreatic cancer.

The team of RBS workers raised £13,000 for the Pancreatic Cancer Action charity.

Their ‘Corporate Dynamos’ team of seven started their journey by calling at Wendy’s house near Chipping Norton, Oxfordshire on Friday, July 8, and ended at Charing Cross station in London on Sunday, July 10.

Wendy, human resources director for RBS Bank corporate division in London, thought she was fit and healthy until a routine check-up four months ago revealed she had pancreatic cancer that had spread to her lungs and liver. Surgery is not an option for the mother- of-two.

Ali Stunt, of Pancreatic Cancer Action charity, and herself a rare survivor of the disease, said she was thrilled that Simon and the team had raised such a significant sum.

“As a charity we are determined to ‘change the numbers’ and create greater awareness of pancreatic cancer amongst the general public, medical community and government, ensuring more people are diagnosed earlier in time for surgery. Wendy is such a wonderful person, her strength of character and zest for life is impressive,” she said.

Simon, who is RBS corporate division’s director of change management, said it was a great team effort. He said: “We are very grateful for the generosity of all our supporters in helping the important work of Pancreatic Cancer Action and supporting our very special colleague Wendy who is an inspiration to us all.”

l Pancreatic cancer is difficult to detect and when diagnosed most people find it is untreatable and their average life expectancy is three to six months. It is the fifth deadliest cancer in the UK but survival figures have stayed the same for 40 years. Survival to one year is less than 20 per cent and to five years three per cent.

To support the Corporate Dynamos visit